Regenerative medicine

We are currently developing hAP cells (hAP (Statin) Cells) in which simvastatin, which is known as a therapeutic agent for hyperlipidemia, is encapsulated in PLGA nanoparticles as Active Pharmaceutical Ingredient(API) and holded to Adipose Derived Mesenchymal Stem Cell(ADMSC).

Simvastatin lowers total blood cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, but on the other hand, it has various biological actions such as anti-inflammatory action and promotion of angiogenesis.

In hAP (statin) cells, holded simvastatin has been reported to be released slowly from Adipose Derived Mesenchymal Stem Cell(Stem Cells Transl Med. 10:1055-1067(2019)), which act as a drug delivery system (DDS).

Other genes related to angiogenesis or anti-inflammation also increase (Stem Cells Transl Med. 10:1055-1067 (2019)), meaning higher cellular intrinsic strength in the hAP-statin cell.

As shown in the above results, where myocardium regeneration is only evident in hAP-stain cell treated mouse, hAP-stain cell is clearly superior to normal ADMSC as therapy of MI.
We have the exclusive license right for hAP-statin cell to treat to myocardial infarction and are accumulating data to start clinical study indicated to MI.

The hAP cell has tremendous potentials to apply to various diseases in combination of drugs and cells. For example, a pharmaceutical substance, whose development was discontinued because of its toxic concern, could be redeveloped as hAP cell since much smaller dose of the substance will be required in the hAP cell. We offer several services include joint research with clients or contract development, according to the client requests.

Please contact us if you have any interests (in case, we might request NDA for much communication with the clients)